IL272374A - Proteins binding nkg2d, cd16 and flt3 - Google Patents

Proteins binding nkg2d, cd16 and flt3

Info

Publication number
IL272374A
IL272374A IL272374A IL27237420A IL272374A IL 272374 A IL272374 A IL 272374A IL 272374 A IL272374 A IL 272374A IL 27237420 A IL27237420 A IL 27237420A IL 272374 A IL272374 A IL 272374A
Authority
IL
Israel
Prior art keywords
nkg2d
binding proteins
flt3 binding
flt3
proteins
Prior art date
Application number
IL272374A
Other languages
English (en)
Hebrew (he)
Inventor
William Haney
Bianka Prinz
Gregory P Chang
Ann F Cheung
Bradley M Lunde
Original Assignee
Dragonfly Therapeutics Inc
William Haney
Bianka Prinz
Gregory P Chang
Ann F Cheung
Bradley M Lunde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc, William Haney, Bianka Prinz, Gregory P Chang, Ann F Cheung, Bradley M Lunde filed Critical Dragonfly Therapeutics Inc
Publication of IL272374A publication Critical patent/IL272374A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
IL272374A 2017-07-31 2020-01-30 Proteins binding nkg2d, cd16 and flt3 IL272374A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762539421P 2017-07-31 2017-07-31
PCT/US2018/044610 WO2019028027A1 (en) 2017-07-31 2018-07-31 PROTEINS BINDING TO NKG2D, CD16 AND FLT3

Publications (1)

Publication Number Publication Date
IL272374A true IL272374A (en) 2020-03-31

Family

ID=65233032

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272374A IL272374A (en) 2017-07-31 2020-01-30 Proteins binding nkg2d, cd16 and flt3

Country Status (15)

Country Link
US (1) US20200165344A1 (enExample)
EP (1) EP3661554A4 (enExample)
JP (3) JP2020529410A (enExample)
KR (2) KR20250051800A (enExample)
CN (1) CN111132698A (enExample)
AU (2) AU2018309712A1 (enExample)
BR (1) BR112020001972A2 (enExample)
CA (1) CA3070986A1 (enExample)
CO (1) CO2020001981A2 (enExample)
EA (1) EA202090387A1 (enExample)
IL (1) IL272374A (enExample)
MA (1) MA49769A (enExample)
MX (1) MX2020001257A (enExample)
SG (1) SG11202000632QA (enExample)
WO (1) WO2019028027A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
MA52206A (fr) 2018-03-27 2021-02-17 Xyphos Biosciences Inc Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EP3902836B1 (en) 2018-12-18 2026-03-25 Boehringer Ingelheim IO Canada Inc. Flt3 agonist antibodies and uses thereof
BR112022007128A2 (pt) * 2019-10-15 2022-07-05 Dragonfly Therapeutics Inc Ligação de proteínas nkg2d, cd16 e flt3
BR112022016550A2 (pt) * 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
JP2024524378A (ja) * 2021-06-29 2024-07-05 山▲東▼先声生物制▲薬▼有限公司 Ｃｄ１６抗体及びその応用
WO2026052582A1 (en) 2024-09-04 2026-03-12 Red Ridge Bio Ag Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077483A1 (en) * 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
ES2573642T3 (es) * 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
EP4310191A3 (en) * 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
EP4050026A1 (en) * 2014-04-01 2022-08-31 Adimab, LLC Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells

Also Published As

Publication number Publication date
BR112020001972A2 (pt) 2020-08-04
WO2019028027A1 (en) 2019-02-07
EA202090387A1 (ru) 2020-05-21
JP2023106433A (ja) 2023-08-01
KR20250051800A (ko) 2025-04-17
AU2025204591A1 (en) 2025-07-10
EP3661554A4 (en) 2021-04-21
EP3661554A1 (en) 2020-06-10
CO2020001981A2 (es) 2020-05-29
MA49769A (fr) 2021-04-21
US20200165344A1 (en) 2020-05-28
KR20200033302A (ko) 2020-03-27
MX2020001257A (es) 2020-08-17
AU2018309712A1 (en) 2020-02-13
CN111132698A (zh) 2020-05-08
CA3070986A1 (en) 2019-02-07
SG11202000632QA (en) 2020-02-27
JP2020529410A (ja) 2020-10-08
JP2025131681A (ja) 2025-09-09

Similar Documents

Publication Publication Date Title
IL268755A (en) Proteins binding her2, nkg2d and cd16
IL268567A (en) Proteins binding bcma, nkg2d and cd16
IL268790A (en) CD33, NKG2D and CD16 binding proteins
IL281305A (en) Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1
SG11202000632QA (en) Proteins binding nkg2d, cd16 and flt3
IL292261A (en) Proteins that bind nkg2d, cd16 and flt3
IL270803A (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
IL270794A (en) NKG2D binding protein, CD16 and ROR1 or ROR2
EP3630181A4 (en) PROTEIN BINDING NKG2D, CD16 AND TUMOR ASSOCIATED ANTIGEN
IL281323A (en) Proteins that bind D2NKG, 16CD, and tumor-associated antigen
IL268574A (en) proteins that bind psma, nkg2d, and cd16
IL268768A (en) Proteins binding gd2, nkg2d and cd16
IL280512A (en) Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EP3643726A4 (en) ANTI-HER2 NANOBODIES, CODING SEQUENCE AND USE OF IT
IL268766A (en) Proteins that bind NKG2D, CD123, and CD16
IL272706A (en) Proteins that bind D2NKG, 16CD, and tumor-associated antigen
LT3452089T (lt) Bispecifiniai surišantys baltymai ir jų panaudojimas
DK3275895T3 (da) Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
ZA202003722B (en) Modified globin proteins
GB201704006D0 (en) Modified globin proteins
ZA201905273B (en) Proteins binding psma, nkg2d and cd16
HK40030226A (en) Proteins binding nkg2d, cd16 and flt3
HK40014039A (en) Proteins binding cd33, nkg2d and cd16
HK40019178A (en) Proteins binding psma, nkg2d and cd16
HK40014030A (en) Proteins binding bcma, nkg2d and cd16